Almirall's Actikerall set for first approvals
This article was originally published in Scrip
Almirall is set to receive its first approvals for Actikerall (5mg/g fluorouracil and 100mg/g salicylic acid) a topical solution for the treatment of actinic keratosis. It has been granted a positive recommendation by regulatory authorities in Germany, the UK, Austria, Luxembourg, Poland, Czech Republic and Slovakia, for the treatment of palpable and/or moderately thick hyperkeratotic actinic keratosis (grade 1/11) in adults.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.